Soft tissue sarcomas (STS) are a diverse group of rare cancers arising from mesenchymal cells — fat, muscle, nerve, fibrous tissue and blood vessels. Modern molecular diagnostics and multidisciplinary care have transformed outcomes, with limb salvage now possible in over 90% of extremity cases.
STS arise from mesenchymal cells and represent more than 70 distinct subtypes. Advances in immunohistochemistry and cytogenetics have refined classification well beyond traditional cell-of-origin categories.
Most STS arise de novo, but recognised risk factors increase vigilance — patients with these warrant regular surveillance.
Latency of 7–10 years after therapeutic radiation.
Industrial agents such as vinyl chloride.
Long-standing limb swelling (Stewart–Treves syndrome).
Li-Fraumeni (p53), NF1 (MPNST), Gardner, Werner, Gorlin, Tuberous sclerosis.
Classified by cell of origin and, increasingly, by cytogenetic findings. Each subtype has unique behaviour, genetics and treatment strategies — dedicated patient guides will be added for each.
Malignant examples: Well-differentiated, dedifferentiated, myxoid & pleomorphic liposarcoma
MDM2 amplification confirms diagnosis in atypical lipomatous tumours.
Malignant examples: Adult fibrosarcoma, myxofibrosarcoma, sclerosing epithelioid fibrosarcoma, DFSP
Includes desmoid tumours — locally aggressive but non-metastasising.
Malignant examples: Tenosynovial giant cell tumour, plexiform fibrohistiocytic tumour
Mostly benign or intermediate behaviour.
Malignant examples: Leiomyosarcoma
Commonly retroperitoneal or uterine; doxorubicin-sensitive.
Malignant examples: Rhabdomyosarcoma family of tumours
Most common STS in children — chemosensitive.
Malignant examples: Angiosarcoma, epithelioid hemangioendothelioma, Kaposi sarcoma
Angiosarcoma may follow radiation or chronic lymphedema.
Malignant examples: Malignant peripheral nerve sheath tumour (MPNST)
Strongly associated with NF1.
Malignant examples: Synovial sarcoma, epithelioid sarcoma, alveolar soft-part, clear cell sarcoma
Molecular tests (e.g. SS18-SSX) confirm diagnosis.
Malignant examples: Undifferentiated pleomorphic sarcoma (UPS)
High grade — managed with multimodal therapy.
Any soft-tissue lump >5 cm or deep to fascia warrants imaging.
Especially if firm, fixed, or rapidly growing.
Change in character of an existing mass is a red flag.
Tingling or weakness may suggest nerve involvement (MPNST).
Early referral to a sarcoma centre prevents misdiagnosis and inappropriate excision.
Size, depth, mobility, neurovascular status and regional lymph nodes.
Gold standard for local extent, tissue characterisation and surgical planning.
Screens for pulmonary metastases — the commonest spread for STS.
Core needle or open biopsy with IHC and molecular tests (e.g. MDM2, SS18-SSX).
AJCC TNM staging combines size, depth, nodal status, metastases and grade. Survival figures apply to extremity STS.
Several features influence prognosis and the intensity of multimodal therapy chosen.
Combined modality treatment — tailored to subtype, grade and site — offers the best long-term control.
The cornerstone of curative treatment. Limb-salvage is achievable in over 90% of extremity sarcomas with modern reconstructive techniques.
Pre- or post-operative radiation improves local control, especially for high-grade or close-margin tumours.
Doxorubicin-based regimens for high-grade or chemosensitive subtypes — rhabdomyosarcoma, Ewing, synovial and myxoid liposarcoma.
For unresectable, recurrent or borderline cases — preserving limbs and function whenever possible.
When a sarcoma is removed without proper pre-operative imaging or biopsy, residual tumour cells are often left behind. Re-excision with wide margins and re-staging at a sarcoma centre is critical — adequate re-surgery plus adjuvant therapy improves outcomes compared with radiotherapy alone after inadequate surgery.
Walk through three real surgical approaches across different subtypes and anatomical sites.
How we plan and execute wide excision for a thigh liposarcoma — preserving muscle, nerves and limb function with multidisciplinary input.
Combining neoadjuvant therapy, precise resection and reconstruction to control a synovial sarcoma around the elbow while preserving joint movement.
A focused look at managing recurrent soft-tissue sarcoma in the forearm — re-staging, re-excision and limb-preserving reconstruction.
A 48-year-old teacher noticed a painless thigh mass for four months. MRI and core biopsy at a sarcoma centre confirmed a high-grade undifferentiated pleomorphic sarcoma. She underwent wide excision, flap reconstruction, adjuvant radiotherapy and six cycles of doxorubicin–ifosfamide chemotherapy. At 5-year follow-up she remains disease-free with full limb function — illustrating the success of coordinated multimodal care.
Lifelong surveillance is essential — most recurrences occur within five years but late events do happen.
Soft tissue sarcomas are rare and complex — outcomes are measurably better when managed by a multidisciplinary team at a high-volume sarcoma centre, combining orthopaedic oncology, medical and radiation oncology, radiology, pathology, reconstructive surgery and rehabilitation.
Share your imaging and biopsy reports — we'll review whether expert sarcoma care, limb-preserving surgery or multimodal therapy is the right next step.
Book an Appointment